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Abstract
Background: Hepatocellular carcinoma (HCC) is supposed to have a venous drainage system to a portal vein,
which makes intrahepatic metastasis possible. However, the mechanism of extrahepatic recurrence, including the
possibility of a direct route to the systemic circulation from the HCC nodules, remains unclear. Therefore, we
performed retrograde hepatic venography for HCC in livers that had been explanted for liver transplantation in
order to explore the possible direct connection between the hepatic vein and HCC nodules.
Methods: Of 105 living-donor liver transplantations (LDLT) performed up to July, 2009 at the Department of
Surgery, Nagasaki University Hospital, dynamic hepatic venography was performed with contrast media under
fluoroscopy for the most recent 13 cases with HCC. The presence of a tumor stain for each HCC case was
evaluated and compared with the histological findings of HCC.
Results: Hepatic venography revealed a tumor stain in 2 of 13 cases (15%). Neither showed any microscopic tumor
invasion of HCC into the hepatic vein. In the other 11 cases, there were 4 microscopic portal venous invasions and
2 microscopic hepatic venous invasions. No patients have shown HCC recurrence in follow-up (median period, 13
months).
Conclusion: Using ex vivo hepatic venography, a direct connection to the hepatic vein from HCC in whole liver
was revealed in 2 cases without demonstrated histopathological invasion to hepatic vein for the first time in the
literature. The finding suggests that there is direct spillage of HCC cells into the systemic circulation via hepatic
vein.
Introduction
Hepatocellular carcinoma (HCC) is one of the most
common malignant tumors and the third most common
cause of cancer-related death in the world [1]. Despite
recent advances in treatments of HCC, the long-term
survival of patients with HCC is still unsatisfactory [2].
Intrahepatic or extrahepatic recurrence usually develops,
even after a curative liver resection or a total hepatect-
omy for orthotopic liver transplantation. There are two
mechanisms that are well known for intrahepatic recur-
rence of HCC: multicentric carcinogenesis due to the
underlying liver disease and intrahepatic metastasis with
venous drainage to a portal vein [3]. On the other hand,
the mechanism of extrahepatic recurrence of HCC is
still controversial, with the possibility of a direct route
from HCC nodules to the systemic circulation still
unconfirmed. According to previous reports, the predic-
tors for extrahepatic recurrence of HCC are the size and
number of tumors, vascular invasion, and elevated
tumor markers [4-8]. However, even cases with small
and single HCC lesions sometimes develop extrahepatic
recurrence.
In this study, we performed hepatic venography for
HCC in explanted livers for liver transplantation, in
order to explore the direct connection between the
hepatic vein and HCC nodules.
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Methods
Patients
One hundred five living-donor liver transplantations
(LDLT) were performed up to July, 2009 at the Depart-
ment of Surgery, Nagasaki University Hospital. Of these
105 LDLTs, we performed hepatic venography on
explanted livers of the most recent 13 cases, which
detected HCC lesions preoperatively and/or postopera-
tively. There were 9 males and 4 females with a median
age at LDLT of 59 years (range; 52-68 years) (Additional
file 1, Table S1).
Ex vivo hepatic venography
Using livers explanted for LDLT, hepatic venography
was performed with contrast media (Urografin, Nihon
Schering, Osaka, Japan) under fluoroscopy. First, a
purse-string suture was placed around the orifice of the
right hepatic vein and the hepatic venous trunk of the
middle and left hepatic vein, respectively, to prevent the
backflow of the contrast media. Second, a plastic needle
was cannulated into the hepatic vein and tightened up
with the purse-string suture. Third, the contrast media
was injected into the hepatic vein by a slow retrograde
bolus injection with very low pressure manually (Figure
1). Thereafter, X-ray images were taken from several dif-
ferent angles in a series.
Evaluation of hepatic venography
We defined the venographic positve case as the presence
of a tumor stain corresponding to an HCC nodule con-
tiguous with hepatic vein, and smoothly filled with con-
trast media without any resistance. The presence of a
tumor stain corresponding to an HCC nodule was
judged to be “positive”, while the absence of a tumor
stain was judged to be “negative” on the serial x-ray
images. The judgment was made by two or three
surgeons.
Statistical analysis
Fisher’s exact test was used for the data analysis. A level
of P < 0.05 was considered to indicate statistical
significance.
Results
Ex vivo hepatic venography
In 2 of 13 cases (15%), tumor stains were confirmed in a
corresponding lesion to indicate the location of an HCC
nodule. One positive case was a 65-year-old male with
2.2-cm HCC located at segment six, associated with
hepatitis C virus-related cirrhosis. The tumor stain from
the right hepatic vein was clearly detected with contrast
media by retrograde hepatic venography (Figure 2). The
other positive case was a 68-year-old male having a 3.2-
cm HCC at segment six. A tumor stain was also seen by
retrograde hepatic venography from the right hepatic
vein (image not shown). The other 11 cases were judged
negative by hepatic venography (Additional file 2, Table
S2). Though negative cases showed no tumor stains
with contrast media, they did show venous compression
from the tumor (Figure 3).
Figure 1 Methods of hepatic venography. 1 Purse-string suture
around the orifice of the hepatic vein (to prevent back flow) 2
Cannulation into the hepatic vein 3 Slow bolus injection of the
contrast media 4 X-ray imaging under fluoroscopy.
Figure 2 A hepatic venography-positive case. A 65-year-old male
with a 2.2-cm HCC at segment 6 (white arrowheads on CT). The
broken circle indicates the site of the tumor. Hepatic venography
shows tumor stains (arrows) corresponding with an HCC nodule. A:
Enhanced CT B: Early phase image of hepatic venography C: Late
phase image of hepatic venography D: magnified image of the late
phase.
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The relationship between hepatic venography and
histopathological findings
Histopathologically, there were 4 portal venous inva-
sions and 2 hepatic venous invasions among the 13
cases. Of the 2 positive hepatic venography cases, one
showed portal venous invasion, but neither showed
microscopic hepatic venous invasion. No statistically sig-
nificant relationship was found between tumor stains by
ex vivo hepatic venography and microscopic hepatic
venous invasion in positive hepatic venography cases.
Outcomes after LDLT
Five of the patients who underwent hepatic venography
died. Two patients died of sepsis, and the other three
died due to liver failure. However, no recurrent HCC
was found in the follow-up (median period, 25 months)
of the 13 cases, including the two patients with venogra-
phically demonstrable HCC, who had follow-up periods
of 35 and 25 months after LT, respectively, at this writ-
ing (Additional file 2, Table S2).
Discussion
In this study, we have demonstrated a direct connection
between primary HCC nodules and the systemic circula-
tion (vena cava) by retrograde hepatic venography with
livers explanted for liver transplantation. To our knowl-
edge, this is the first report to visualize the direct com-
munication from HCC nodules to the systemic
circulation in explanted whole livers from liver trans-
plantation. In this study, 2 of 13 cases showed tumor
stains, which indicate direct venous drainage to the
hepatic vein (or vena cava), by hepatic venography. The
stains might represent HCC cells or tumor thrombi
spilled from the primary HCC into systemic circulation
and thereby likely to be carried to distant organs by the
bloodstream. In spite of the presence of a direct connec-
tion to the hepatic veins, neither of the two positive
cases showed microscopic hepatic venous invasion.
These results suggest that the route of the cancer cells
into the vessels could be independent of histopathologi-
cal invasion.
Based on previous reports, various factors are thought
to contribute to extrahepatic recurrence; for instance,
Funaki et al. reported hematogenous spreading of HCC
cells from the primary tumor [9]. Recently, some studies
have reported that adhesion molecules, such as E-cad-
herin [10,11] or CD44 [12,13], play an important role in
the extrahepatic recurrence of HCC after hepatectomy
or liver transplantation. Other reports have indicated
that the presence of cancer stem cells is a key factor
[14,15]. In any case, cancer cells from the primary lesion
likely migrate into the bloodstream of systemic circula-
tion to form metastatic foci in distant organs.
Moreover, several factors seem to be involved in the
occurrence of distant metastasis, such as 1) escape from
local immunity, 2) connection to systemic circulation, 3)
spilling of HCC cells from the primary lesion into the
bloodstream, 4) escape from the host immune surveil-
lance systems, 5) adhesion to another organ, and 6)
growth. A recent study represents a case of metastasis
without pathological venous invasion. Sugino et al.
[16,17] described sinusoidal angiogenesis as a non-inva-
sive mechanism of blood-borne metastasis in HCC; i.e.,
an invasion-independent metastasis pathway. This may
suggest that patients after liver transplantation need par-
ticularly vigilant observation for extrahepatic recurrence
because of their immunosuppressive states.
In addition, the possibility of intrahepatic metastasis as
well as extrahepatic metastasis via systemic circulation
has also been reported [18]. Thus, patients having HCC
with a direct connection to systemic circulation should
be monitored, not only for extrahepatic recurrence but
also for intrahepatic recurrence, even after liver
transplantation.
There are some reports of efferent vessels of HCC.
Mitsunobu et al. [19] demonstrated that the portal vein
serves as an efferent vessel in advanced HCC by direct
injection of radiopaque media into HCC nodules of
resected specimens. Other reports have made similar
conclusions from different points of view, namely, histo-
pathological study [20] or color Doppler imaging exami-
nation using ultrasonography [21]. Those previous
reports suggested the following mechanism. The efferent
vessel of hepatic tumors is basically the hepatic vein;
Figure 3 A hepatic venography-negative case. A 58-year-old
male with multiple HCCs. A 6.2-cm HCC at segment 4 (white
arrowheads). The broken circle indicates the site of the tumor.
Hepatic venography shows no tumor stain but venous compression
from the tumor (arrows). A: Enhanced CT, early phase B: Enhanced
CT, delayed phase C: Image of hepatic venography D: Magnified
image of hepatic venography.
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blood from the HCC still flows out to the hepatic vein
at its early stage. With the progress of HCC, the portal
vein also acts as an efferent vessel. It is supposed that a
capsule is formed as the HCC undergoes dedifferentia-
tion, resulting in regurgitation of blood to the portal
vein with the rising internal pressure of HCC nodule.
This causes intrahepatic metastasis through the portal
vein as well.
In regard to the outcomes of LDLTs for the 13
patients, there has been no recurrence of HCC so far.
This may be due to the fact that the follow-up periods
are not very long (37 months at most), and that all
cases except one were within the Milan criteria [22].
Conclusion
Hepatic venography of 2 of 13 livers explanted for
HCC-related LDLT revealed a direct connection
between primary HCC nodules and the hepatic vein.
Such cases should be strictly observed for extrahepatic
and intrahepatic recurrence, even in cases within the
Milan criteria and without microscopic hepatic venous
invasion.
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